Who Paid My Doc
James Feeney
Interventional Cardiology Provo, UT Medical Doctor
NPI 1386624377 CMS profile 243885
395 W Bulldog Blvd, Provo, UT 84604
General payments
$6,556
Research payments
$102
Ownership & investment interest
$0
Through program year 2024, James Feeney of Provo, UT is reported in the CMS Open Payments database as having received $6,556 across 313 general payments and $102 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 46th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
6 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2024 | Research | $102 | 1 | |
| 2023 | General | $78 | 4 | |
| 2022 | General | $514 | 3 | |
| 2021 | General | $141 | 4 | |
| 2020 | General | $1,833 | 105 | |
| 2019 | General | $3,990 | 197 |
Beside peers
- James Feeney
- Interventional Cardiology median
- Middle half of Interventional Cardiology
- National median
In program year 2025, general payments to James Feeney were reported at $0. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.
Show as a table
| Year | James Feeney | Interventional Cardiology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $3,990 | $1,097 | $329–$3,048 | $163 |
| 2020 | $1,833 | $473 | $161–$1,480 | $114 |
| 2021 | $141 | $677 | $233–$1,827 | $132 |
| 2022 | $514 | $978 | $333–$2,724 | $149 |
| 2023 | $78 | $1,136 | $382–$2,986 | $160 |
| 2024 | $0 | $1,181 | $395–$3,326 | $164 |
| 2025 | $0 | $1,092 | $366–$3,019 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 30 drugsPart D claims
1,726
Drug cost
$375,283
Branded share of claims
29%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Jardiance Empagliflozin | Brand | 104 | $118,898 | |
| Eliquis Apixaban | Brand | 100 | $109,592 | |
| Entresto Sacubitril/Valsartan | Brand | 53 | $65,884 | |
| Xarelto Rivaroxaban | Brand | 14 | $21,023 | |
| Farxiga Dapagliflozin Propanediol | Brand | 12 | $13,755 | |
| Repatha Sureclick Evolocumab | Brand | 22 | $12,250 | |
| Lokelma Sodium Zirconium Cyclosilicate | Brand | 12 | $9,490 | |
| Metoprolol Succinate | Generic | 200 | $3,164 | |
| Rosuvastatin Calcium | Generic | 133 | $2,676 | |
| Clopidogrel Clopidogrel Bisulfate | Brand | 122 | $2,146 |
The 10 drugs with the highest cost, of 30 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 50 billing codesPaid by Medicare
$62,060
Medicare patients
1,045
Services billed
1,682
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 50% | |
| Ischemic heart disease | 47% | |
| Chronic kidney disease | 38% | |
| Diabetes | 37% | |
| Heart failure | 36% | |
| Atrial fibrillation | 34% | |
| Depression | 31% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
314 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Interventional Cardiology in Utah
Vamsee Yaganti
Interventional Cardiology · Salt Lake City, UT
Blake Gardner
Interventional Cardiology · St George, UT
Anwar Tandar
Interventional Cardiology · Salt Lake City, UT
Sanjeev Trehan
Interventional Cardiology · Ogden, UT
Stavros Drakos
Interventional Cardiology · Salt Lake City, UT
Tareq Harb
Interventional Cardiology · Ogden, UT
Related records
Interventional Cardiology in Utah
Practitioners in the same specialty and state, ranked by reported value.
All Interventional Cardiology
Everyone recorded under this specialty, nationwide.
Doctors in Utah
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.